

Long-acting regimens for the future

Alex R Rinehart, PhD


Medicine Development Leader, Prevention

ViiV Healthcare



Novel MOA'S offer multiple options for development of new LA regimens

<p>1</p> <p>GSK3810109A Class: bNAb Phase: II</p>	<p>2</p> <p>NRTTI 1 Class: NRTTI Phase: Pre-clinical</p> <p>NRTTI 2 Class: NRTTI Phase: Pre-clinical</p>	<p>3</p> <p>Capsid Class: Capsid Inhibitor Phase: Pre-clinical</p>	<p>4</p> <p>Cabotegravir for PrEP Class: INSTI Phase: III</p> <p>Cabotegravir Q2M Class: INSTI Phase: III</p>	<p>4</p> <p>Cabotegravir400 Class: INSTI Phase: I</p> <p>VH4524184 Class: INSTI Phase: Pre-Clinical</p>	<p>5</p> <p>Capsid Class: Capsid Inhibitor Phase: Pre-clinical</p>	<p>6</p> <p>GSK3640254 Class: Maturation Inhibitor Phase: II</p> <p>GSK3739937 Class: Maturation Inhibitor Phase: I</p>
---	---	--	--	--	--	--



Integrase inhibitor-based LA regimens anchor current and future pipeline

Data delivery	Regimen selection	Targeted launch window		
2022-2023	2024	2025-2027	2027+	2030+
<p>2022 CAB 400 Ph I CAB + PH20 Ph I N6LS + PH20 Ph 1 N6LS Ph IIa</p> <p>2023 NRTTI + PH20 Ph I/IIa Capsid + PH20 Ph I/IIa Rilpivirine TBD</p> <p>2023 study start CAB + N6LS Ph IIb</p>	<p>By 2024 Partner selection for self-administered regimen to progress to Ph 2b/3</p> <p>Partner selection for ultra long-acting regimen to progress to Ph 2b/3</p>	<p>1st self-administered long-acting regimen for treatment</p> <p>Ultra-long acting cabotegravir for prevention with PH20</p>	<p>Ultra-long acting ≥Q3M for treatment — Cabotegravir + novel MOAs</p>	<p>Ultra-long acting ≥Q6M for treatment — VH184 + novel MOAs</p> <p>HIV Cure</p>